Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Citrate on Inflammation and Lipids in Hemodialysis
NCT02661295Phase 4Terminated
- Sponsor
- NYU Langone Hospital – Long Island
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric citrate in hyperphosphatemia and chronic inflammation, sponsored by NYU Langone Hospital – Long Island. Primary endpoints: Percent Change in Total Cholesterol at 6 months, Percent Change in LDL-Cholesterol at 6 months and 9 more. Started Jul 2015; status: terminated.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemiachronic inflammation
Beyond the preview
Go deeper on NCT02661295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661295.